• Users Online: 87
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2018  |  Volume : 16  |  Issue : 1  |  Page : 81-86

Evaluation of microRNA-155 as a diagnostic serum-based biomarker in patients with breast cancer


1 Department of Clinical Pathology, Faculty of Medicine (Boys), Al-Azhar University, Cairo, Egypt
2 Department of Surgery, Faculty of Medicine (Boys), Al-Azhar University, Cairo, Egypt
3 Department of Clinical Pathology, National Research Center, Cairo, Egypt

Correspondence Address:
Nader Abd-Alhamid
Department of Surgery, Faculty of Medicine (Boys), Al-Azhar University, Cairo
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/AZMJ.AZMJ_47_18

Rights and Permissions

Background Breast cancer (BC) is the most common cancer among Egyptian women, and its early detection is accompanied with decreased mortality rates. MicroRNAs (miRNAs) are small noncoding RNA molecules that regulate gene expression and affect cancer development. The expression level of miRNA-155 is up-regulated in BC and correlates with its invasive properties, offering a great potential as a noninvasive biomarker for BC screening. Objective The aim of this study is to evaluate the role of miRNA-155 as an early diagnostic serum-based biomarker of BC. Patients and methods This study was conducted on 30 patients newly diagnosed with BC and associated 20 healthy women as a control group. Serum level of miRNA-155 was measured for all studied cases using real-time quantitative PCR technique. Results MiRNA-155 expression was up-regulated in serum of patients with BC compared with control group (P<0.001). Serum miRNA-155 expression significantly differed with cancer stage and its expression directly increased with advancing cancer stage. A comparative study of the miRNA-155 expression between control group and positive and negative metastatic lymph nodes (LNs) subgroups demonstrates a highly significant difference. MiRNA-155, in terms of fold change, is highest in positive LNs metastatic subgroup, with a mean of 19.63, followed by 4.29 in negative LNs metastasis subgroup, and lowest in the control group, with a mean of 1.06 (P<0.001). Conclusion The results validate miRNA-155 as a promising diagnostic and even a prognostic marker in cases of BC.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed42    
    Printed2    
    Emailed0    
    PDF Downloaded9    
    Comments [Add]    

Recommend this journal